News

   

Oxolife Appoints International Fertility Experts to its Scientific Advisory Board

Leading experts in fertility and human reproduction with…

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Trial expected to reach the primary endpoint of progression…

Poolbeg Pharma plc – Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma

Poolbeg team boosted by highly experienced executives with track…

Lytix Biopharma presents third quarter 2023 results

Oslo, 09 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext…

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

Lytix Biopharma presenting at major investor conferences in London and Stockholm in November

Oslo, 8 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext…

Vicore to Present at the Stifel 2023 Healthcare Conference

Stockholm, November 7, 2023 – Vicore Pharma Holding AB…

Futura expands partnership with M8 Pharmaceuticals for remainder of Central and South American region

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the…

Futura Medical – Eroxon Awarded “New Product of the Year, Healthcare” by Boots

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the…

iOnctura to Present Research on Roginolisib and IOA-359 at ASH

Three abstracts accepted by ASH with two poster presentations Geneva,…

Poolbeg Pharma plc – POLB 001 Data to be Presented at American Society of Hematology Annual Meeting

Potential to address cancer treatment related Cytokine Release…

Vicore Pharma: Interim report July-September 2023

Stockholm, November 2, 2023 – Vicore Pharma Holding AB (STO:…

Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023

CAMBRIDGE, UK, 2 November 2023 – Mission Therapeutics (“Mission”),…

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Non-clinical data demonstrate clear impact of immune modulating…

STORM Therapeutics Appoints Marguerite Hutchinson, J.D., as Chief Business Officer

1 November 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM),…

iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ

Roginolisib is in development for solid and hematologic malignancies…

Leucid Bio to Participate in Upcoming Healthcare Conferences

London, UK – 31 October 2023 – Leucid Bio ("Leucid" or the…

Futura Medical Granted Marketing Authorisation for Eroxon® in Mexico

Futura Medical plc (AIM: FUM), the pharmaceutical company developing…

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

Invizius Limited (“Invizius”), a biotechnology company developing…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.